Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To assess somatoform disorder (SFMD) prevalence and impact in Parkinson disease (PD) and dementia with Lewy bodies (DLB).
Methods: SFMD were assessed by direct observation of symptoms in the year coincident (±6 months) with definite diagnosis of PD, DLB, Alzheimer disease, multiple system atrophy, progressive supranuclear palsy, or frontotemporal dementia, and by interviews with patients, caregivers, and general practitioners, and reviews of prior hospital admissions, in a cohort of 942 patients with neurodegenerative disorders. Matched groups of patients with PD and patients with DLB without vs with SFMD were selected for comparisons and followed up over 4 years.
Results: The frequency of SFMD was higher in DLB (15 patients, 12%) and PD (29 patients, 7%) than in other neurodegenerative diseases (0%–3%). SFMD consisted of conversion motor or sensory disorders, often accompanied by delusional thought content; in one patient catatonic symptoms were observed concomitantly with PD diagnosis. Evidence of SFMD symptoms, preceding diagnosis by 6 months–10 years, was obtained in 28 patients with PD and all patients with DLB. A total of 22 patients with PD and all patients with DLB could be followed for 4 years. SFMD symptoms recurred during follow-up, with catatonic signs developing in 9 patients with PD and 8 patients with DLB. Most baseline demographic and clinical features did not differ between subjects with or without SFMD. Decline of cognitive function was greater in PD-SFMD patients than in those without SFMD (p < 0.01); it was comparable to that observed in DLB.
Conclusions: The frequency of somatoform disorder (SFMD) (with catatonic signs) in Parkinson disease and dementia with Lewy bodies suggests that SFMD are part of the spectrum of Lewy body diseases.
Glossary
- AD=
- Alzheimer disease;
- ANOVA=
- analysis of variance;
- BDI=
- Beck Depression Inventory;
- CAF=
- Clinician Assessment of Fluctuations;
- DLB=
- dementia with Lewy bodies;
- DRS-2=
- Dementia Rating Scale–2;
- DSM-IV=
- Diagnostic and Statistical Manual of Mental Disorders, 4th edition;
- FAB=
- Frontal Assessment Battery;
- FTD=
- frontotemporal dementia;
- GP=
- general practitioner;
- H&Y=
- Hoehn & Yahr;
- MMSE=
- Mini-Mental State Examination;
- MSA=
- multiple system atrophy;
- NPI=
- Neuropsychiatric Inventory;
- PD=
- Parkinson disease;
- PDD=
- Parkinson disease with dementia;
- PSP=
- progressive supranuclear palsy;
- SCL-90R=
- Symptom Checklist-90-R;
- SFMD=
- somatoform disorder;
- UPDRS=
- Unified Parkinson's Disease Rating Scale.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.